NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

You need to read the JAMA paper carefully. This is what was mentioned in the paper. Anyone who has common senses know what it means.

"Eight of the 232 patients (3.4%) receiving DCVax-L were treated with tumor-treating fields (TTF) following recurrence. Four of those 8 patients (50.0%) continued receiving DCVax-L while using the TTF device after recurrence and survived from 22.6 to more than 72.7 months from randomization. Four of the 8 patients (50.0%) stopped receiving DCVax-L while using the TTF device post-recurrence, and survived from 8.9 to 29.2 months from randomization."

Don't get up your hope too much on the NSCLC trial. Can the armor thinge get T-cell infiltrate into tumor tissue? The answer is no. If there are no t cells, how could checking point inhibitors work? Is it simple enough to understand?